IMR Press / FBL / Special Issues / 1396637513225261058

Cancer of unknown primary site of origin: is it time to solve the labyrinth?

Submission deadline: 20 May 2022
Special Issue Editors
Giulia M. Stella, MD
Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Interests: Identification of target biomarkers of malignant pleural mesothelioma and design of new therapeutic approaches based on the application of nanotechnologies; Study of biomarkers of lung cancer, with particular reference to the role of the MET oncogene in the process of metastatic dissemination; Study of the molecular profile of metastatic tumors with occult primitiveness; More recently I have been interested in studying the common biomolecular mechanisms between cancer and pulmonary fibrosis
Special Issue Information

Dear Colleagues,

Over the past few years, the improved knowledge on the biological, genetic and molecular heterogeneity of tumors, together with the development of pharmacological technologies has allowed the identification of molecular targets for novel therapeutic strategies. This rapidly evolving process has led to the overall reconsideration of the biological and genetic peculiarities that characterize each malignant disease. The identification of patients likely to respond to specific treatments according to the presence of relevant molecular targets (personalized medicine) needs clinical studies focused on a constant and productive interaction among the professionals with a significant background in the various disciplines.

Despite relevant progresses some malignant entities are still obscure and, in some cases, for instance, their own origin cannot be easily identified. These enigmatic cases, representing about 3% of all cancer diagnosis, are defined as cancers of unknown primary (CUP)and represent a constant challenge in both clinical and translational oncology. Growing amount of data are available regarding the biologic landscape of CUP as well as novel techniques to identify the putative site of organ, and many results will be available in the next few years. Those finding will help to both clarify pathogenic mechanisms and to identify actionable therapeutic targets.

The present issue aims at summarizing state of the art data on biology and clinical management of CUPs as well at collecting novel experimental results from basic and translation research approaches.

Dr. Giulia M. Stella

Guest Editor

Keywords
Cancer of Unknown Primary
Malignant Disease
Clinical and Translational Oncology
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top